Clinical Trial Update: Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GDC-0853 versus placebo and adalimumab in rheumatoid arthritis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GDC-0853

Snippet

Sponsor: Genentech, Inc. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2019-09-10